Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.41 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.38 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.38 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.36 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 0.36 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.36 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.36 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.36 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.36 |
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.36 |
| ▸ | PRKCA known ✓ | P17252 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28803186 | 1.00 | ADRB2 (0.41) | ADRB2GRM2GRM3BLMPMP22 | |
| Hydrochloric Acid SCHEMBL31123028 | 1.00 | ADRB2 (0.41) | ADRB2GRM2GRM3BLMPMP22 | |
| Hydrochloric Acid SCHEMBL15210760 | 1.00 | ADRB2 (0.41) | ADRB2GRM2GRM3BLMPMP22 | |
| SCHEMBL1237466 | 0.98 | ADRB2 (0.42) | ADRB2GRM2GRM3BLMPMP22 | |
| SCHEMBL2129702 | 0.98 | ADRB2 (0.42) | ADRB2GRM2GRM3BLMPMP22 | |
| SCHEMBL31447563 | 0.98 | ADRB2 (0.42) | ADRB2GRM2GRM3BLMPMP22 | |
| SCHEMBL3719566 | 0.98 | ADRB2 (0.42) | ADRB2GRM2GRM3BLMPMP22 | |
| Hydrochloric Acid SCHEMBL3707227 | 0.85 | AKT1 (0.44) | BLMACHECA1CA2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28802982 | 0.85 | AKT1 (0.44) | BLMACHECA1CA2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31123038 | 0.85 | AKT1 (0.44) | BLMACHECA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2817299-B1 | SUBSTITUTED CHROMAN COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LTD (IN) | 2019-06-12 | — | — | EP | disclosed |
| US-9987249-B2 | Substituted chroman compounds as calcium sensing receptor modulators | LUPIN LIMITED (IN) | 2018-06-05 | — | — | US | disclosed |
| US-20170209410-A1 | SUBSTITUTED CHROMAN COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2017-07-27 | — | — | US | disclosed |
| US-9598391-B2 | Substituted chroman compounds as calcium sensing receptor modulators | LUPIN ATLANTIS HOLDINGS SA (CH) | 2017-03-21 | — | — | US | disclosed |
| US-20150368222-A1 | SUBSTITUTED CHROMAN COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2015-12-24 | — | — | US | disclosed |
| US-9163001-B2 | Substituted chroman compounds as calcium sensing receptor modulators | LUPIN LIMITED (IN) | 2015-10-20 | — | — | US | disclosed |
| US-20150038546-A1 | SUBSTITUTED CHROMAN COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2015-02-05 | — | — | US | disclosed |
| EP-2817299-A1 | SUBSTITUTED CHROMAN COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | Lupin Limited (IN) | 2014-12-31 | — | — | EP | disclosed |
| US-8785494-B2 | Calcium sensing receptor modulating compounds and pharmaceutical use thereof | LEO-PHARMA A/S (DK) | 2014-07-22 | — | — | US | disclosed |
| US-8765676-B2 | Calcium sensing receptor modulating compounds and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2014-07-01 | — | — | US | disclosed |
| US-20130267516-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2013-10-10 | — | — | US | disclosed |
| US-20130261132-A1 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2013-10-03 | — | — | US | disclosed |
| US-20130244995-A1 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2013-09-19 | — | — | US | disclosed |
| US-20130245084-A1 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2013-09-19 | — | — | US | disclosed |
| WO-2013124828-A1 | SUBSTITUTED CHROMAN COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-08-29 | — | — | WO | disclosed |
| US-20120129926-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-05-24 | — | — | US | disclosed |
| US-20120122784-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261132-A1 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS | CASR, CALCR, PTH1R | ADRB2 261/4885ACHE 2738/4885CA2 13/4885 |
| US-20150368222-A1 | SUBSTITUTED CHROMAN COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | CASR, RYR2, CALCR | ADRB2 271/4885ACHE 1790/4885CA2 24/4885 |
| US-20120129926-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | CASR, CALCR, ORAI1 | ADRB2 240/4885ACHE 2734/4885CA2 41/4885 |
| US-20130245084-A1 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS | CASR, CALCR, PTH1R | ADRB2 233/4885ACHE 2420/4885CA2 16/4885 |
| US-20170209410-A1 | SUBSTITUTED CHROMAN COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | CASR, RYR2, CALCR | ADRB2 271/4885ACHE 1790/4885CA2 24/4885 |
| US-20130244995-A1 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS | CASR, CALCR, PTH1R | ADRB2 261/4885ACHE 2738/4885CA2 13/4885 |
| US-20130267516-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | CASR, PTH1R, CALCR | ADRB2 173/4885ACHE 2171/4885CA2 16/4885 |
| US-20150038546-A1 | SUBSTITUTED CHROMAN COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | CASR, RYR2, CALCR | ADRB2 271/4885ACHE 1790/4885CA2 24/4885 |
| US-20120122784-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | CASR, SARAF, ORAI1 | ADRB2 235/4885ACHE 2823/4885CA2 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.